HMG20B Antikörper (AA 1-100)
-
- Target Alle HMG20B Antikörper anzeigen
- HMG20B (High Mobility Group 20B (HMG20B))
-
Bindungsspezifität
- AA 1-100
-
Reaktivität
- Maus
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser HMG20B Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))
- Kreuzreaktivität
- Maus
- Homologie
- Human,Rat,Cow
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human BRAF35
- Isotyp
- IgG
- Top Product
- Discover our top product HMG20B Primärantikörper
-
-
- Applikationshinweise
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- Haltbarkeit
- 12 months
-
- Target
- HMG20B (High Mobility Group 20B (HMG20B))
- Andere Bezeichnung
- BRAF35 (HMG20B Produkte)
- Hintergrund
-
Synonyms: BRAF25, BRAF35, BRCA 2 Associated Factor 35 kDa, BRCA2 associated factor 35, BRCA2-associated factor 35, High Mobility Group Protein 20B, HM20B_HUMAN, HMG 20B, HMG box containing protein 20B, HMG box-containing protein 20B, HMG domain-containing protein 2, HMG domain-containing protein HMGX2, hmg20b, HMGX2, PP7706, pp8857, SMARCE1 related protein, SMARCE1-related protein, SMARCE1r, sox like, Sox like transcriptional factor, Sox-like transcriptional factor, SOXL, Structural DNA binding protein BRAF35, Structural DNA-binding protein BRAF35, SWI/SNF related, SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily E member 1 related, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related.
Background: The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45 % of families with high incidence of breast cancer and at least 80 % of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.
- Gen-ID
- 10362
-